Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in Refractory Stage IV Breast Cancer
NCT00244881Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cediranib in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Circulating Endothelial Cells at 3 weeks and Objective Response Rate at 7 years. Started Sep 2005; status: completed.
02
Drugs
cediranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00244881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00244881.